



Supply Disruption Alert

SDA/2021/009

Issued: 02 August 2021

Glipizide (Minodiab[®]) 5mg tablets

Summary

- Glipizide 5mg tablets are out of stock until mid-October 2021.
- Prescribers will need to review all affected patients and assess ongoing need for glipizide.
- If ongoing treatment is required, consideration should be given to prescribing an alternative sulfonylurea or glucose lowering medication.
- Alternative glucose-lowering medications, including sulfonylureas, remain available.
- Patients with monogenic diabetes* (MODY) should remain on an equivalent dose of an alternative sulfonylurea.
- Unlicensed supplies of glipizide 5mg tablets have been sourced and may be considered where the above options are inappropriate.

*an autosomal dominant, genetic form of diabetes where a change in a single gene is responsible for glucose dysregulation, where patients would have been identified through genetic testing

Action

All healthcare professionals in primary, secondary or specialist healthcare services who prescribe or supply glipizide tablets should be aware of the following advice:

All patients

- Clinicians should defer initiating new patients on glipizide tablets until the supply disruption is resolved; and
- Counsel patients on potential side-effects and new dose regime if prescribing alternative glucose-lowering medications.

Primary Care - for patients with insufficient supplies of glipizide

- GP practices should identify all affected patients and:
 - review ongoing need for glipizide taking into consideration the risk of hypoglycaemia, age, frailty status, and the patient's HbA1c;
 - if ongoing treatment with glipizide is required, consider prescribing an equivalent dose of gliclazide immediate release tablets. Based on clinical experience, 5 mg of glipizide should be roughly equivalent to 80 mg of gliclazide;
 - if gliclazide immediate release tablets are not appropriate, consider prescribing an alternative sulfonylurea (see advice below);
 - if alternative glucose-lowering medications may be more appropriate, discuss these options with the patient, considering their individual preferences, characteristics and comorbidities;

- if none of the above options are suitable, consider prescribing unlicensed glipizide tablets (see advice below; prescribers should work with local pharmacy teams to ensure orders are placed within appropriate time frames as lead times may vary);
 - arrange appropriate follow-up and monitoring as recommended in [national guidelines](#); and
 - make early contact with specialists in secondary care for advice on management options if required.
- When licensed glipizide tablets are resupplied, GP practices should review patients prescribed an alternative agent and discuss appropriate next steps and management.

Secondary Care - for patients with insufficient supplies of glipizide, clinicians should:

- identify all affected patients under their care (including those referred by primary care); and
- ensure patients are reviewed in a timely manner, that individualised management plans are agreed and enacted and communicated to the patient's GP practice.

Product details

Glipizide (Minodiab[®]) 5mg tablets (Pfizer)

Problem / background

Pfizer are out of stock of glipizide (Minodiab[®]) 5mg tablets until mid-October 2021 due to increased demand following the withdrawal of another glipizide 5mg tablet from the UK market.

Advice on switching patients to alternate sulfonylureas

Sulfonylureas are insulin secretagogues that act mainly by augmenting insulin secretion.

Glipizide is licensed for the treatment of adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet and exercise to lower the blood glucose in relation to meals.

There are alternative drugs in the sulfonylurea class that remain on the market including gliclazide, glimepiride and tolbutamide. See Table 1 for further information.

Table 1

Sulfonylurea	Daily dose	Peak plasma concentration	Half-life
Glipizide	2.5-20mg (once daily but doses above 15mg should be divided)	1 to 3 hours	2 to 4 hours
Gliclazide*	40 to 320mg (once daily but doses above 160mg should be administered twice a day)	2 to 6 hours	10 to 12 hours
Glimepiride	1-6mg	~2.5 hours	5 to 8 hours
Tolbutamide	0.5-2g (once daily or in divided doses)	3 to 4 hours	4 to 8 hours

*based on clinical experience, 5 mg of glipizide should be roughly equivalent to 80 mg of gliclazide

Other classes of glucose lowering drug may be considered appropriate with choice based on patients' preferences, comorbidities and factors that are usually taken into account when diabetes treatment is modified e.g. co-existing obesity, cardiovascular disease, impaired renal function, frailty, etc.

See [NICE guidance](#) for alternative treatment options to licensed indications for glipizide.

Unlicensed imports

The following specialist importers have confirmed they can source unlicensed glipizide 5mg tablets (please note, there may be other companies that can also source supplies):

- Alium Medical
- Mawdsley's Unlicensed
- Waymade PLC

Any decision to prescribe an unlicensed medicine must consider the relevant guidance and NHS Trust or local governance procedures. Please see the links below for further information:

- [The supply of unlicensed medicinal products](#), Medicines and Healthcare products Regulatory Agency
- [Professional Guidance for the Procurement and Supply of Specials](#), Royal Pharmaceutical Society
- [Prescribing unlicensed medicines](#), General Medical Council (GMC)

When prescribing a product that is not licensed in the UK due to a supply issue with the licensed alternative, prescribers must indicate on the FP10 prescription that an unlicensed product is required. This can be done in one of the following two ways:

- Electronic prescriptions – if the required unlicensed product is shown on electronic prescribing systems, GPs should select:
 - Glipizide 5mg tablets (imported)
- Paper prescriptions – where the unlicensed product is not shown on electronic prescribing systems, GPs should use a paper prescription and annotate with the following wording: “**special order**”.

Distribution

Trusts (NHS boards in Scotland)

CAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:

- | | |
|---|--|
| • A&E consultants | • Endocrinologists |
| • A&E departments | • Equipment stores |
| • A&E nurses | • Equipment libraries and stores |
| • All departments | • Haematologists |
| • Cardiologists | • Hospital pharmacies |
| • Cardiology departments | • Hospital pharmacists |
| • Cardiology nurses | • Intensive care medical staff |
| • Cardiothoracic surgeons | • Intensive care nursing staff (adult) |
| • Cardiothoracic surgery directors | • Intensive care units |
| • Cardiothoracic departments | • Intensive care, directors of |
| • Chief pharmacists | • Medical directors |
| • Clinical governance leads | • NHS walk-in centres |
| • Clinical Procurement Specialists | • Occupation health departments |
| • Community hospitals | • Outpatient clinics |
| • Community nurses | • Palliative care teams |
| • Day surgery units | • Paramedics |
| • Diabetologists | • Pharmaceutical advisors |
| • Dieticians | • Pharmacists |
| • District nurses | • Purchasing managers |
| • EBME departments | • Respiratory specialists |
| • Emergency Preparedness and Response officer | • Risk managers |

- Supplies managers
- Walk-in centres

NHS England regional teams

For onward distribution to all relevant staff including:

- Community Pharmacists

General Practice

For onward distribution to all relevant staff including:

- General practitioners
- Nutritional nurse specialists
- General practice managers
- General practice nurses
- Non-medical prescribers in General Practice

Independent distribution**Establishments registered with the Care Quality Commission (CQC) (England only)**

- Adult placement
- Care homes providing nursing care (adults)
- Care homes providing personal care (adults)
- Clinics
- Domiciliary care providers
- Further education colleges registered as care homes
- Hospices
- Hospitals in the independent sector
- Independent treatment centres
- Nursing agencies
- Private medical practitioners

Enquiries

Send enquiries about this notice to the DHSC Medicines Supply Team, quoting reference number

SDA/2021/009 - Email: DHSCmedicinesupplyteam@dhsc.gov.uk